Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAD 402
- Development stage
- Phase 2
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RAD 402 is an investigational radiopharmaceutical being developed for the treatment of advanced prostate cancer. It consists of the radioactive isotope Terbium-161 (Tb-161) linked to a proprietary monoclonal antibody that targets Kallikrein-related peptidase 3 (KLK3), a protein highly expressed in prostate cancer cells but with limited expression in healthy tissue. This targeted approach aims to deliver cytotoxic radiation directly to tumor cells while sparing normal tissues. The mechanism leverages both the specificity of monoclonal antibody targeting and the therapeutic effects of beta-emitting Tb-161, which may offer advantages over existing radiotherapeutics such as reduced kidney toxicity and improved efficacy against micrometastatic disease. Developed by Radiopharm Theranostics, with isotope supply from TerThera, RAD 402 is expected to enter Phase I clinical trials for advanced prostate cancer[1][3][4][6].
- Other names
- RAD-402RAD402RAD 402
02
Targets
PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on RAD 402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAD 402.